Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/49771

TitleMetabolic alterations underlying Bevacizumab therapy in glioblastoma cells
Author(s)Miranda-Gonçalves, Vera
Carneiro, Diana
Valbom, Inês
Cury, Fernanda Paula
Silva, Viviane Aline
Granja, Sara Costa
Reis, R. M.
Baltazar, Fátima
Martinho, Olga
KeywordsAnti-angiogenic therapy
Bevacizumab
Glioblastoma
Glycolytic metabolism
Issue date27-Nov-2017
PublisherImpact Journals
JournalOncotarget
CitationMiranda-Gonçalves, V., Cardoso-Carneiro, D., Valbom, I., Cury, F. P., Silva, V. A., Granja, S., ... & Martinho, O. (2017). Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells. Oncotarget, 8(61), 103657.
Abstract(s)Anti-VEGF therapy with Bevacizumab is approved for glioblastoma treatment, however, it is known that tumors acquired resistance and eventually became even more aggressive and infiltrative after treatment. In the present study we aimed to unravel the potential cellular mechanisms of resistance to Bevacizumab in glioblastoma in vitro models. Using a panel of glioblastoma cell lines we found that Bevacizumab is able to block the secreted VEGF by the tumor cells and be internalized to the cytoplasm, inducing cytotoxicity in vitro. We further found that Bevacizumab increases the expression of hypoxic (HIF-1α and CAIX) and glycolytic markers (GLUT1 and MCT1), leading to higher glucose uptake and lactate production. Furthermore, we showed that part of the consumed glucose by the tumor cells can be stored as glycogen, hampering cell dead following Bevacizumab treatment. Importantly, we found that this change on the glycolytic metabolism occurs independently of hypoxia and before mitochondrial impairment or autophagy induction. Finally, the combination of Bevacizumab with glucose uptake inhibitors decreased in vivo tumor growth and angiogenesis and shift the expression of glycolytic proteins. In conclusion, we reported that Bevacizumab is able to increase the glucose metabolism on cancer cells by abrogating autocrine VEGF in vitro. Define the effects of anti-angiogenic drugs at the cellular level can allow us to discover ways to revert acquired resistance to this therapeutic approaches in the future
TypeArticle
URIhttp://hdl.handle.net/1822/49771
DOI10.18632/oncotarget.21761
ISSN1949-2553
Publisher versionhttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=21761&path[]=69048
Peer-Reviewedyes
AccessOpen access
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
49.pdf4,67 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID